Events & Presentations Corporate Presentation Date Documents October 10, 2024 Corporate Presentation - October 2024 Upcoming Events There are currently no events to display. Archived Investor Events and Presentations Archived Scientific Presentations Date Event Details Summary Toggle Dec 04, 2024 at 3:50 PM EST 7th Annual Evercore HealthCONx Conference Listen to Webcast Summary Toggle Dec 03, 2024 at 2:00 PM EST Piper Sandler 36th Annual Healthcare Conference Listen to Webcast Date Documents December 9, 2024 ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy October 10, 2024 UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease March 6, 2024 Vudalimab (PD-1 x CTLA-4) Monotherapy in mCRPC - Clinical Update with Additional Data November 3, 2023 SITC 2023: A phase 1, first-in-human, open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors April 17, 2023 AACR 2023: Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors December 12, 2022 ASH 2022: A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis November 10, 2022 A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Patients With Relapsed or Refractory Clear Cell Renal Cell Carcinoma November 10, 2022 A Phase 2 Study of Vudalimab, a PD-1 × CTLA-4 Bispecific Antibody, Plus Chemotherapy or Targeted Therapy in Patients With Molecularly Defined Subtypes of Metastatic Castration-Resistant Prostate Cancer November 10, 2022 A Phase 2 Study of Vudalimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer December 12, 2021 Phase 1 Safety and Anti-tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma November 12, 2021 SITC 2021: Preliminary Clinical Experience With Vudalimab, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors April 10, 2021 Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells November 9, 2020 Preliminary Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of XmAb®20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors November 9, 2020 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors June 22, 2020 AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies December 9, 2019 ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL March 4, 2019 Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format November 9, 2018 SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation April 16, 2018 AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation November 13, 2017 SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T CellActivation and Proliferation April 4, 2017 AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation November 9, 2016 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation November 9, 2016 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation December 7, 2014 American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111
